chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose, Blood glucose increased, Blood pressure measurement, Body temperature, Burning sensation
Clinical narrative: face and hands turned red; whites of my eyes were red as well; burning up and hot to the touch; small rash on multiple body locations; lump in the back of my throat; My hands swelled; My body temperature was also at a low grade fever; BP, heart rate, and sugar levels were abnormally high; BP, heart rate, and sugar levels were abnormally high; BP, heart rate, and sugar levels were abnormally high; This is a spontaneous report from a contactable consumer (patient). A 37-year-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Solution for Injection Lot Number: EL9265) via an unspecified route of administration in right arm on 11Feb2021 at 15:30 as dose 2, single (at the age of 37-years-old); and previously received first dose of BNT162B2 (Lot Number:EL8982) via an unspecified route of administration in left arm on 15Jan2021 at 10:30 as dose 1, single (at the age of 37-years-old); both for COVID-19 immunization at hospital. Medical history included Crohn's, Ulcerative Colitis, Premature Menopause; all from an unknown date and unknown if ongoing. Patient had known allergy to sulfa. Concomitant medications within 2 weeks of vaccination included BUPROPION, DHEA, BUSPIRONE, ESTRADIOL; all taken for an unspecified indication, start and stop date were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19 and did not receive any other vaccines within 4 weeks. On 13Feb2021, 2 days after the second vaccination, the patient experienced a small rash on multiple body locations. On 14Feb2021, 3 days after the second vaccine, Patient had  face and hands turned red, and it moved inward to cover the top half of body. The whites of her eyes were red as well. Patient was burning up and hot to the touch all over. No hives and no itching. It was reported on an unspecified date in Feb2021, patient also felt like she had a lump in the back of throat, and experienced hands swelled, body temperature was also at a low-grade fever. At the ED, it was noted patient's Blood pressure (BP), heart rate, and sugar levels were abnormally high and had no history of any of those being high. The patient underwent lab tests and procedures in Feb2021, which included blood glucose, blood pressure measurement, heart rate resulted as high on an unspecified date; and body temperature was low-grade fever on an unspecified date. Since the vaccination, the patient has not been tested for COVID-19. Adverse event resulted in emergency room/department or urgent care. Treatment received was steroids, pepcid, Benadryl. The outcome of events was unknown.  Follow-Up (08Jul2021): Follow-up attempts are completed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Heart rate, Heart rate increased, Hypertension, Ocular hyperaemia
Clinical narrative: face and hands turned red; whites of my eyes were red as well; burning up and hot to the touch; small rash on multiple body locations; lump in the back of my throat; My hands swelled; My body temperature was also at a low grade fever; BP, heart rate, and sugar levels were abnormally high; BP, heart rate, and sugar levels were abnormally high; BP, heart rate, and sugar levels were abnormally high; This is a spontaneous report from a contactable consumer (patient). A 37-year-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Solution for Injection Lot Number: EL9265) via an unspecified route of administration in right arm on 11Feb2021 at 15:30 as dose 2, single (at the age of 37-years-old); and previously received first dose of BNT162B2 (Lot Number:EL8982) via an unspecified route of administration in left arm on 15Jan2021 at 10:30 as dose 1, single (at the age of 37-years-old); both for COVID-19 immunization at hospital. Medical history included Crohn's, Ulcerative Colitis, Premature Menopause; all from an unknown date and unknown if ongoing. Patient had known allergy to sulfa. Concomitant medications within 2 weeks of vaccination included BUPROPION, DHEA, BUSPIRONE, ESTRADIOL; all taken for an unspecified indication, start and stop date were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19 and did not receive any other vaccines within 4 weeks. On 13Feb2021, 2 days after the second vaccination, the patient experienced a small rash on multiple body locations. On 14Feb2021, 3 days after the second vaccine, Patient had  face and hands turned red, and it moved inward to cover the top half of body. The whites of her eyes were red as well. Patient was burning up and hot to the touch all over. No hives and no itching. It was reported on an unspecified date in Feb2021, patient also felt like she had a lump in the back of throat, and experienced hands swelled, body temperature was also at a low-grade fever. At the ED, it was noted patient's Blood pressure (BP), heart rate, and sugar levels were abnormally high and had no history of any of those being high. The patient underwent lab tests and procedures in Feb2021, which included blood glucose, blood pressure measurement, heart rate resulted as high on an unspecified date; and body temperature was low-grade fever on an unspecified date. Since the vaccination, the patient has not been tested for COVID-19. Adverse event resulted in emergency room/department or urgent care. Treatment received was steroids, pepcid, Benadryl. The outcome of events was unknown.  Follow-Up (08Jul2021): Follow-up attempts are completed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling, Pyrexia, Rash, Sensation of foreign body
Clinical narrative: face and hands turned red; whites of my eyes were red as well; burning up and hot to the touch; small rash on multiple body locations; lump in the back of my throat; My hands swelled; My body temperature was also at a low grade fever; BP, heart rate, and sugar levels were abnormally high; BP, heart rate, and sugar levels were abnormally high; BP, heart rate, and sugar levels were abnormally high; This is a spontaneous report from a contactable consumer (patient). A 37-year-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Solution for Injection Lot Number: EL9265) via an unspecified route of administration in right arm on 11Feb2021 at 15:30 as dose 2, single (at the age of 37-years-old); and previously received first dose of BNT162B2 (Lot Number:EL8982) via an unspecified route of administration in left arm on 15Jan2021 at 10:30 as dose 1, single (at the age of 37-years-old); both for COVID-19 immunization at hospital. Medical history included Crohn's, Ulcerative Colitis, Premature Menopause; all from an unknown date and unknown if ongoing. Patient had known allergy to sulfa. Concomitant medications within 2 weeks of vaccination included BUPROPION, DHEA, BUSPIRONE, ESTRADIOL; all taken for an unspecified indication, start and stop date were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19 and did not receive any other vaccines within 4 weeks. On 13Feb2021, 2 days after the second vaccination, the patient experienced a small rash on multiple body locations. On 14Feb2021, 3 days after the second vaccine, Patient had  face and hands turned red, and it moved inward to cover the top half of body. The whites of her eyes were red as well. Patient was burning up and hot to the touch all over. No hives and no itching. It was reported on an unspecified date in Feb2021, patient also felt like she had a lump in the back of throat, and experienced hands swelled, body temperature was also at a low-grade fever. At the ED, it was noted patient's Blood pressure (BP), heart rate, and sugar levels were abnormally high and had no history of any of those being high. The patient underwent lab tests and procedures in Feb2021, which included blood glucose, blood pressure measurement, heart rate resulted as high on an unspecified date; and body temperature was low-grade fever on an unspecified date. Since the vaccination, the patient has not been tested for COVID-19. Adverse event resulted in emergency room/department or urgent care. Treatment received was steroids, pepcid, Benadryl. The outcome of events was unknown.  Follow-Up (08Jul2021): Follow-up attempts are completed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Lymphadenopathy, Pain
Clinical narrative: Body ache; Fatigue; Swollen lymph nodes under left arm; Chills; low grade fever; bruise on left arm just under injectionsite.; This is a spontaneous report from a contactable healthcare professional, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA Vaccine; Lot number: EL3247), via an unspecified route of administration in the left arm on 25Mar2021 at 10:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included allergic to sulfa (sulfonamide drugs). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medication included norethisterone acetate, ethinylestradiol, ferrous fumarate (BLISOVI 24FE) taken for an unknown indication from an unknown date. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA Vaccine; Lot number: EL3247), via an unspecified route of administration in the left arm on 04Mar2021 at 10:30  (at the age of 42-years-old) as a single dose for COVID-19 immunisation. On 26Mar2021, the patient experienced chills with low-grade fever after 14 hours of vaccination. On 27Mar2021 after 18 hours of vaccination, the patient experienced fatigue and body ache, a swollen lymph node under the left clavicle. On an unknown day in Mar2021, the patient had a bruise on the left arm, just under the injection site which was present about 20 hours after vaccination. Therapeutic measures were taken as a result of chills with low-grade fever, fatigue, body aches, swollen lymph nodes, bruise on the left arm and included treatment with ADVIL. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events low-grade fever was resolved on 27Mar2021 after a duration of 6 hours and bruises was recovered on an unknown day in Mar2021; chills was recovering; while the events of fatigue, body ache, swollen lymph nodes were not recovered at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site bruising
Clinical narrative: Body ache; Fatigue; Swollen lymph nodes under left arm; Chills; low grade fever; bruise on left arm just under injectionsite.; This is a spontaneous report from a contactable healthcare professional, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA Vaccine; Lot number: EL3247), via an unspecified route of administration in the left arm on 25Mar2021 at 10:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included allergic to sulfa (sulfonamide drugs). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medication included norethisterone acetate, ethinylestradiol, ferrous fumarate (BLISOVI 24FE) taken for an unknown indication from an unknown date. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA Vaccine; Lot number: EL3247), via an unspecified route of administration in the left arm on 04Mar2021 at 10:30  (at the age of 42-years-old) as a single dose for COVID-19 immunisation. On 26Mar2021, the patient experienced chills with low-grade fever after 14 hours of vaccination. On 27Mar2021 after 18 hours of vaccination, the patient experienced fatigue and body ache, a swollen lymph node under the left clavicle. On an unknown day in Mar2021, the patient had a bruise on the left arm, just under the injection site which was present about 20 hours after vaccination. Therapeutic measures were taken as a result of chills with low-grade fever, fatigue, body aches, swollen lymph nodes, bruise on the left arm and included treatment with ADVIL. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events low-grade fever was resolved on 27Mar2021 after a duration of 6 hours and bruises was recovered on an unknown day in Mar2021; chills was recovering; while the events of fatigue, body ache, swollen lymph nodes were not recovered at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Large increase in my pre-existing tinnitus in my left ear; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old male patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 18Mar2021 at 10:00 (at the age of 67-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension and tinnitus. The patient had no known medication allergies. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in Mar2021, the patient experienced large increase in his pre-existing tinnitus in left ear. The adverse events had not resulted in doctor or other healthcare professional office/clinic visit/ emergency visit/ department or urgent care. The patient did not receive treatment for the reported event worsening of tinnitus. The clinical outcome of tinnitus was not recovered.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, SARS-CoV-2 test, Vaccination site pain
Clinical narrative: Lightheaded after injection for a few hours.; Pain at injection sites for about two days; This is a spontaneous report from a non-contactable consumer. A 30-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA Vaccine; Lot number: unknown), via an unspecified route of administration in the left arm on 25Mar2021 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had a history of allergy to prawns. No concomitant medications were reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was tested for COVID-19 which included Color COVID-19 test via nasal swab on an unknown date in Mar 2021 where the result found to be negative. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 25Mar2021, after the vaccination, the patient had experienced lightheaded after injection for a few hours and had pain at injection sites for about two days. No therapeutic measures, were taken for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event lightheaded after injection for a few hours was resolved on unknown date in Mar2021, while the outcome of pain at injection sites resolved on 27Mar2021. No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Fatigue
Clinical narrative: fatigue; chills; loss of appetite; This is a spontaneous report from a non-contactable consumer. A female patient of unspecified age received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration on 27Mar2021, as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On unknown date in Mar2021, the patient experienced fatigue, chills, loss of appetite. Treatment received for the adverse events was reported as unknown. The clinical outcome of the events of fatigue, chills and loss of appetite was unknown.   No follow-up attempts are possible. Information about lot/ batch number cannot be obtained.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm; This is a spontaneous report from a contactable consumer. A 47-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via unspecified route of administration in the left arm on 05Mar2021 at 16:30 (at the age of 47-years-old) and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via unspecified route of administration in the left arm on 26Mar2021(at the age of 47-years-old) as a single dose for COVID-19 immunisation. The patient medical history included asthma. The patient was allergic to sulfas. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), naproxen sodium (ALEVE) and fexofenadine hydrochloride (ALLEGRA) from unknown dates, for unknown indications and unknown if ongoing. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 06Mar2021, the patient experienced sore arm. The patient did not receive any treatment for the event sore arm. The event did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The clinical outcome of the event sore arm was resolved o an unspecified date.   No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Nausea, Vertigo
Clinical narrative: Severe Vertigo; nausea; dizziness; This is a spontaneous report received from a contactable healthcare professional, the patient. A 62-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208), via an unspecified route of administration in the left arm on 27Mar2021 at 08:45 (at the age of 62-years-old), as a single dose for COVID-19 immunisation. Medical history included osteogenesis imperfecta and osteoporosis. Concomitant medication included diclofenac (VOLTAREN) via topical route for an unspecified indication from unknown date. The patient previously took VIOXX for an unspecified indication and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021 at 04:00, the patient experienced severe vertigo, nausea, and dizziness onset while sleeping. The events did not result in doctor or other healthcare professional office/clinic visit, and the emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the severe vertigo, nausea, and dizziness was recovering (also reported as the events lasted for approximately 8 hours and now 48 hours after injection nearly completely resolved).  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Dizziness, Fatigue, Headache
Clinical narrative: Extreme headache; chills; fatigue; aches; dizziness; nausea; Fever lasting over 24 hours/temp over 101,; This is a spontaneous report from a contactable consumer, the patient. A 53-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: Unknown) via an unspecified route of administration in left arm on 25Mar2021 at 08:30 (at the age of 53-years-old) as single for COVID-19 immunisation. The patient did not have any medical history. The patient did not have any allergies to medications, food, or other products. The patient did not receive any other medications within 2 weeks of COVID-19 vaccine. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient had not been tested for COVID-19. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: Unknown) via an unspecified route of administration in left arm on 05Mar2021 at 07:30 (at the age of 53-years-old) as single for COVID-19 immunisation. on 25Mar2021 at 20:30, the patient experienced extreme headache, temperature over 101 (UNSPECIFIED UNIT), chills, aches, fatigue, dizziness, nausea. Fever lasted over 24 hours and symptoms persisted over 48 hours. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, chills, aches, fatigue, dizziness, nausea were recovered on an unknown date; while that of fever was recovered on 25Mar2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain, Pyrexia
Clinical narrative: Extreme headache; chills; fatigue; aches; dizziness; nausea; Fever lasting over 24 hours/temp over 101,; This is a spontaneous report from a contactable consumer, the patient. A 53-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: Unknown) via an unspecified route of administration in left arm on 25Mar2021 at 08:30 (at the age of 53-years-old) as single for COVID-19 immunisation. The patient did not have any medical history. The patient did not have any allergies to medications, food, or other products. The patient did not receive any other medications within 2 weeks of COVID-19 vaccine. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient had not been tested for COVID-19. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: Unknown) via an unspecified route of administration in left arm on 05Mar2021 at 07:30 (at the age of 53-years-old) as single for COVID-19 immunisation. on 25Mar2021 at 20:30, the patient experienced extreme headache, temperature over 101 (UNSPECIFIED UNIT), chills, aches, fatigue, dizziness, nausea. Fever lasted over 24 hours and symptoms persisted over 48 hours. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, chills, aches, fatigue, dizziness, nausea were recovered on an unknown date; while that of fever was recovered on 25Mar2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: M
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Headaches started and have not stoped; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 20Mar2021 at 11:30 as a single dose for COVID-19 immunisation. Medical history included high blood pressure and high cholesterol. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN) of 5mg, rosuvastatin (MANUFACTURER UNKNOWN) of 20mg, losartan (MANUFACTURER UNKNOWN) of 50 mg used for unknown indication from an unspecified date. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had not been tested positive for COVID-19 since having the vaccine. On 23Mar2021 at 24:00, the patient experienced headache. It was reported that, the event resulted in doctor or other healthcare professional office/clinic visit. The patient received treatment for the reported events was reported as unknown. The clinical outcome of the event headache was not resolved at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Nausea, Pain in extremity, Somnolence
Clinical narrative: Very brief period of nausea; Slight drowsiness lingering; Soreness in arm on side that received injection; Soreness in shoulder; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 28Mar2021 at 12:00 (at the age of 27-years-old), as a single dose for COVID-19 immunisation. Medical history was reported as none. Concomitant medications included men daily multivitamin (MANUFACTURER UNKNOWN) and daily fiber supplement (MANUFACTURER UNKNOWN); both taken for unknown indication from unknown date. The patient had no known allergies to medications, food or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021 at 12:15, the patient experienced very brief period of nausea, some slight drowsiness lingering to about 2-3 hours after injection and soreness in shoulder/arm on side that received injection which lasted till approximately 21 hours. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcomes of the events nausea, drowsiness pain in arm and shoulder pain was resolving at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Headache, Pain, Pyrexia
Clinical narrative: Headache; Body aches; Feverish; Very weak; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8733), via an unspecified route of administration in the left arm on 28Mar2021 at 12:15 (at the age of 27-years-old), as single dose for COVID-19 immunisation.  Medical history included epilepsy and chronic asthma. The patient did not have any allergies to medications, food or other products. Concomitant medications included leviteracetam (MANUFACTURER UNKNOWN), nitrofurantoin (MANUFACTURER UNKNOWN), CBD (MANUFACTURER UNKNOWN), Vitamin C (MANUFACTURER UNKNOWN) and Vitamin B (MANUFACTURER UNKNOWN); all taken for unknown indication from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6205), via an unspecified route of administration in the left arm on 07Mar2021 at 11:45 (at the age of 27-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 29Mar2021 at 00:00; the patient experienced body aches, feverish, headache and very weak. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events body aches, feverish, headache, and very weak were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Pain, Pyrexia
Clinical narrative: Aches; fever 100.3; tired; minor chills; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: EP6955) via an unspecified route of administration on 25Mar2021 at 14:00 (at the age of 57-years-old) in left arm as a single dose for COVID-19 immunisation. Medical history included being treated for atrial fibrillation since an unknown date. Concomitant medications included apixaban (ELIQUIS) and diltiazem (CARDIZEM) for an unknown indication and from an unknown date. The patient previously received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: EL3241) via an unspecified route of administration on 04Mar2021 at 14:30 in left arm as a single dose for COVID-19 immunisation. The patient previously received BACTRIM and KEFLEX both from an unknown date for an unspecified indications and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 26Mar2021 at 07:30 the patient experienced aches, fever when checked 100.3, and felt tired and minor chills. The patient did not receive any treatment for adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of the events aches, fever, tiredness with minor chills were recovered on an unknown date in Mar2021.  No follow-up attempts are needed. No further information expected.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling abnormal, Headache
Clinical narrative: Slight headache; Brain fog; This is a spontaneous report received from a contactable consumer, the patient. A 47-Years old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) as a single dose via an unspecified route of administration in his right arm on 25Mar2021 (at the age of 47-years-old), as a single dose for COVID-19 immunisation. The patients medical history was reported as none. Concomitant medications included regular vitamins and tamsulosin hydrochloride (FLOWMAX) received within 2 weeks of vaccination. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER6202) as a single dose via an unspecified route of administration in his right arm on 25Feb2021 at 17:00 (at the age of 47-years-old), as a single dose for COVID-19 immunisation. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient had not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient had not tested for COVID-19. On 28Mar2021, the patient experienced slight headache and brain fog. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcomes for the events slight headache and brain fog were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Hypokinesia, Muscle rigidity, Muscle tightness, Musculoskeletal stiffness, Neck pain
Clinical narrative: Stiffness; rigidity in the muscles; tightness; when bending or moving myneck with sharp pain.; Limited range of motion reduced my ability to flex and extendmy neck and bend or rotate my headfrom side to side; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6209) via an unspecified route of administration in the left arm on 25Mar2021 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198) via an unspecified route of administration in the left arm on 04Mar2021 at 11:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 28Mar2021, at 4:00, the patient experienced stiffness, tightness and rigidity in the muscles, when bending or moving patient felt sharp neck pain, limited range of motion and had reduced her ability to flex, extend neck and bend or rotate her head from side to side. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the adverse events. The clinical outcomes of the events stiffness, tightness, rigidity in the muscles, neck with sharp pain and limited range of motion were recovering at the time of this report.    No follow up attempts are possible. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Ear pain, Neck pain, Pain in jaw, Tenderness
Clinical narrative: extreme pain on left sideof neck; pain extended to ear; pain on occasion moved to lower jaw; tenderness in theneck; This is a spontaneous report received from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN 6205) via an unspecified route of administration in the left arm on 11Mar2021at 12:00 (at the age of 61-years-old), as a single dose for COVID-19 immunisation. Medical history included hashimoto thyroid. Concomitant medications included Levothyroxine sodium (UNITHROID) from an unknown date for unknown indication which was received within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER6201) via an unspecified route of administration in the left arm on 18Feb2021 at 16:00 (at the age of 61-years-old), as a single dose for COVID-19 immunisation. The patient had a history of allergy to eggs and corn. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. The patient was not diagnosed with COVID-19 prior to vaccination. On 25Mar2021 at 08:30, the patient had experienced extreme pain on left side of her neck, at the base of her skull and was not relieved with ibuprofen. The pain extended to her ear and on occasion moved to her lower jaw. The following day, the pain was only at the base of her skull but on both left and right. By the 3rd day, the pain had moved to the right side primarily and on the 4th day to the right side only, radiating to the right ear, but later in the day back to left centre of her neck. For the entire 4 days, she struggled to use the muscles in her neck at times. At other times she felt she was straining the muscles. Stretching helped, when she could isolate the muscle. At times she found relief with ice or heat, at other times ice or heat caused more distress. she still had tenderness in the neck, but the pain had dissipated. Adverse events resulted in a visit to the doctors or other healthcare professional office/clinic visit. The patient received ibuprofen and treatment from a chiropractor for the reported events. The clinical outcome of the events extreme pain on left side of neck, pain extended to ear, pain on occasion moved to lower jaw and tenderness in the neck was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle strain, Musculoskeletal stiffness
Clinical narrative: Stiffness in arm at the injection site; Muscle pull; This is a spontaneous report received from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: En6204) via an unspecified route of administration in the left arm on 13March2021 at 18:30 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient did not have any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 13March2021, the patient had experienced arm stiffness at the injection site and felt like the muscle being pulled. The patient did not received any treatment for the events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of event stiffness in arm and muscle pull was not recovered. No follow-up attempts are possible. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Myalgia
Clinical narrative: Chills; Muscle pain; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955), via an unspecified route of administration on 24Mar2021 14:00 in left arm (at the age of vaccination 59-year-old), as a single dose for COVID-19 immunisation. Medical history includes hypothyroidism. The patient had no known allergies. Concomitant history includes Levothyroxine sodium (LEVOXYL) started on an unknown date for unknown indication. The past drug history includes that the patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247), via an unspecified route of administration to left arm on 3Mar2021 14:30 (at the age of 59-year-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021 14:30, the patient had experienced chills, muscle pain. The patient did not receive any treatment for events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events chills and muscle pain was recovered on an unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Arthralgia, Body temperature, Chills, Dizziness
Clinical narrative: stomach cramps; dizziness; axillary lymph node enlargement and pain; Fever 102; body aches; severe chills; joint pain; headache; nausea; axillary lymph node enlargement; local site reaction/pain; local site reaction/pain; This is a spontaneous report from a contactable healthcare professional, the patient.  A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an intramuscular route of administration in the left arm on 25Mar2021 at 09:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension and hypothyroidism. Concomitant medications included HCTZ (hydrochlorothiazide) (MANUFACTURER UNKNOWN), Withania somnifera (ASHWAGANDHA), levothyroxine (MANUFACTURER UNKNOWN), losartan (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202), via an intramuscular route of administration in the left arm on 04Mar2021 at 09:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. The patient previously received morphine (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 25Mar2021 at 19:00, the patient experienced fever 102, severe chills, body aches, joint pain, headache, nausea, stomach cramps, dizziness, local site reaction/pain, and axillary lymph node enlargement and pain. The symptoms began 10 hours post injection and lasted 48 hours. The patient did not receive any treatment for events fever, chills, general body pain, joint pain, headache, nausea, stomach cramps, dizziness, axillary lymph nodes enlarged, vaccination site pain, vaccination site reaction and lymph node pain. The clinical outcomes of the events fever, chills, general body pain, joint pain, headache, nausea, stomach cramps, dizziness, axillary lymph nodes enlarged, vaccination site pain, vaccination site reaction and lymph node pain were recovered on 27Mar2021 at 19:00.   No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Lymph node pain, Lymphadenopathy, Nausea, Pain
Clinical narrative: stomach cramps; dizziness; axillary lymph node enlargement and pain; Fever 102; body aches; severe chills; joint pain; headache; nausea; axillary lymph node enlargement; local site reaction/pain; local site reaction/pain; This is a spontaneous report from a contactable healthcare professional, the patient.  A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an intramuscular route of administration in the left arm on 25Mar2021 at 09:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension and hypothyroidism. Concomitant medications included HCTZ (hydrochlorothiazide) (MANUFACTURER UNKNOWN), Withania somnifera (ASHWAGANDHA), levothyroxine (MANUFACTURER UNKNOWN), losartan (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202), via an intramuscular route of administration in the left arm on 04Mar2021 at 09:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. The patient previously received morphine (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 25Mar2021 at 19:00, the patient experienced fever 102, severe chills, body aches, joint pain, headache, nausea, stomach cramps, dizziness, local site reaction/pain, and axillary lymph node enlargement and pain. The symptoms began 10 hours post injection and lasted 48 hours. The patient did not receive any treatment for events fever, chills, general body pain, joint pain, headache, nausea, stomach cramps, dizziness, axillary lymph nodes enlarged, vaccination site pain, vaccination site reaction and lymph node pain. The clinical outcomes of the events fever, chills, general body pain, joint pain, headache, nausea, stomach cramps, dizziness, axillary lymph nodes enlarged, vaccination site pain, vaccination site reaction and lymph node pain were recovered on 27Mar2021 at 19:00.   No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site pain, Vaccination site reaction
Clinical narrative: stomach cramps; dizziness; axillary lymph node enlargement and pain; Fever 102; body aches; severe chills; joint pain; headache; nausea; axillary lymph node enlargement; local site reaction/pain; local site reaction/pain; This is a spontaneous report from a contactable healthcare professional, the patient.  A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an intramuscular route of administration in the left arm on 25Mar2021 at 09:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension and hypothyroidism. Concomitant medications included HCTZ (hydrochlorothiazide) (MANUFACTURER UNKNOWN), Withania somnifera (ASHWAGANDHA), levothyroxine (MANUFACTURER UNKNOWN), losartan (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202), via an intramuscular route of administration in the left arm on 04Mar2021 at 09:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. The patient previously received morphine (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 25Mar2021 at 19:00, the patient experienced fever 102, severe chills, body aches, joint pain, headache, nausea, stomach cramps, dizziness, local site reaction/pain, and axillary lymph node enlargement and pain. The symptoms began 10 hours post injection and lasted 48 hours. The patient did not receive any treatment for events fever, chills, general body pain, joint pain, headache, nausea, stomach cramps, dizziness, axillary lymph nodes enlarged, vaccination site pain, vaccination site reaction and lymph node pain. The clinical outcomes of the events fever, chills, general body pain, joint pain, headache, nausea, stomach cramps, dizziness, axillary lymph nodes enlarged, vaccination site pain, vaccination site reaction and lymph node pain were recovered on 27Mar2021 at 19:00.   No follow-up attempts are needed. No further information is expected.